2024
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649.
Elimova E, Shitara K, Moehler M, Ajani J, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary J, Bruges Maya R, Karamouzis M, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Feeney K, Wang R, Nathani R, Janjigian Y. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649. Journal Of Clinical Oncology 2024, 42: 4040-4040. DOI: 10.1200/jco.2024.42.16_suppl.4040.Peer-Reviewed Original ResearchProgression-free survivalBlinded independent central reviewCombined positive scoreObjective response ratePD-L1Overall survivalFollow-upCheckMate 649Clinically meaningful progression-free survivalPD-L1 combined positive scoreProgression-free survival benefitProgrammed death-ligand 1Dual primary endpointsHER2+ patientsDeath-ligand 1Analysis of OSIndependent central reviewLong-term efficacyFollow-up resultsEarly Follow-upClinically Meaningful ImprovementsMedian OSOS benefitPD-1Central reviewNivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
Shitara K, Moehler M, Ajani J, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary J, Elimova E, Bruges Maya R, Karamouzis M, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Feeney K, Wang R, Nathani R, Janjigian Y. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649. Journal Of Clinical Oncology 2024, 42: 306-306. DOI: 10.1200/jco.2024.42.3_suppl.306.Peer-Reviewed Original ResearchProgression-free survivalBlinded independent central reviewCombined positive scoreObjective response ratePD-L1Overall survivalFollow-upCheckMate 649Clinically meaningful progression-free survivalPD-L1 combined positive scoreProgression-free survival benefitProgrammed death-ligand 1Dual primary endpointsHER2+ patientsDeath-ligand 1Analysis of OSIndependent central reviewLong-term efficacyFollow-up resultsEarly Follow-upClinically Meaningful ImprovementsMedian OSOS benefitPD-1Central review
2017
Combined Elbow Release and Humeral Rotational Osteotomy in Arthrogryposis
Ramirez R, Richards C, Kozin S, Zlotolow D. Combined Elbow Release and Humeral Rotational Osteotomy in Arthrogryposis. The Journal Of Hand Surgery 2017, 42: 926.e1-926.e9. PMID: 28716382, DOI: 10.1016/j.jhsa.2017.06.005.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentArthrogryposisBone NailsBone PlatesChildChild, PreschoolCohort StudiesCombined Modality TherapyContractureElbowExercise TherapyFemaleHumansHumerusMaleOrthopedic ProceduresOsteotomyPostoperative CarePrognosisRadiographyRange of Motion, ArticularRecovery of FunctionRetrospective StudiesRotationTreatment OutcomeConceptsArc of motionElbow extension contracturesPosterior elbow releaseMidterm follow-upElbow releaseEarly Follow-upFollow-upHumeral rotational osteotomyExtension contractureRetrospective chart review of consecutive patientsChart review of consecutive patientsReview of consecutive patientsInternal rotation contractureAvailable follow-up dataLong-term follow-upHumeral osteotomyRetrospective chart reviewDate of surgeryRotational osteotomyYear Follow-UpFollow-up dataElbow extensionRotation contractureStatistically significant differenceConsecutive patients
2008
Association of Early Follow-up After Acute Myocardial Infarction With Higher Rates of Medication Use
Daugherty SL, Ho PM, Spertus JA, Jones PG, Bach RG, Krumholz HM, Peterson ED, Rumsfeld JS, Masoudi FA. Association of Early Follow-up After Acute Myocardial Infarction With Higher Rates of Medication Use. JAMA Internal Medicine 2008, 168: 485-491. PMID: 18332293, DOI: 10.1001/archinte.168.5.485.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAspirinContinuity of Patient CareEvidence-Based MedicineFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedMyocardial InfarctionPoisson DistributionProportional Hazards ModelsProspective StudiesRegistriesRegression AnalysisTreatment OutcomeConceptsAcute myocardial infarctionMedication useMyocardial infarctionMultivariable analysisEarly outpatientEvidence-based medication useProspective Registry Evaluating OutcomesSecondary analysisEarly Follow-upBeta-blocker useUse of aspirinCurrent guideline recommendationsPrimary care physiciansEvidence-based therapiesHigh rateEligible patientsStatin useClinical characteristicsHospital dischargePrimary outcomeCare physiciansGuideline recommendationsMedication prescriptionsFollow-upEvaluating Outcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply